2019
463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)
Eu J, Yadav K, Lim Y, Hirpara J, Kong L, Ng Z, Lee V, Lee S, Tan D, Soo R, Chee C, Yong W, Sundar R, Lim J, Wang L, Ohi N, Tsunoda T, Pervaiz S, Goh B, Wong A. 463P Evaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC). Annals Of Oncology 2019, 30: v174. DOI: 10.1093/annonc/mdz244.025.Peer-Reviewed Original ResearchMitochondrial membrane potentialSerum metabolomeHER2+ breast cancerOncogene-addicted tumorsDose-finding phaseClinically tolerable dosesCancer stem cellsNon-significant riseG3/4 toxicitiesOxidative phosphorylation inhibitionSignificantly with treatmentGIST patientsTolerated doseTumor biopsiesImmunohistochemistry expressionCopy numberOxidative phosphorylationSerum lactateBreast cancerClinical developmentDrug resistanceMerck SeronoDose levelsDay 1Pathway inhibitor
2016
Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?
Giuliano K, Nagarajan N, Canner J, Najafian A, Wolfgang C, Schneider E, Meyer C, Lennon AM, Johnston FM, Ahuja N. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? Journal Of Surgical Oncology 2016, 115: 351-357. PMID: 27885685, DOI: 10.1002/jso.24514.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsCause-specific mortalityGIST patientsDiagnosis of GISTCases of GISTLarge nation-wide studyGastric gastrointestinal stromal tumorsGastric GIST patientsCommon mesenchymal tumorsFive-year survivalApproval of imatinibNation-wide studySEER databaseStromal tumorsMesenchymal tumorsGastrointestinal tractAge 50PatientsSurvival analysisSimilar outcomesTumorsPrevious reportsFrequent useOutcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply